This document is a publication of a patent application (US20260085279A1) filed by Daesang Corporation with the USPTO. The application describes a novel mutant strain of Corynebacterium bacteria that has been engineered to enhance the production of L-arginine or L-citrulline. The modification targets the acetylglutamate kinase enzyme within the L-arginine biosynthesis pathway, resulting in increased productivity compared to existing strains.

While this is a patent application and not a regulation imposing direct compliance obligations, it is relevant for companies in the biotechnology and pharmaceutical sectors involved in amino acid production. Companies developing or utilizing similar microbial strains for L-arginine or L-citrulline synthesis should be aware of this intellectual property filing. The publication date of March 26, 2026, indicates when this information became publicly available, and the filing date was November 24, 2025.